Salmon calcitonin: a review of current and future therapeutic indications

被引:159
作者
Chesnut, C. H., III [1 ]
Azria, M. [2 ]
Silverman, S. [3 ]
Engelhardt, M. [2 ]
Olson, M. [2 ]
Mindeholm, L. [2 ]
机构
[1] Univ Washington, Osteoporosis Res Grp, Seattle, WA 98195 USA
[2] Novartis Pharma AG, Basel, Switzerland
[3] Cedars Sinai Med Ctr, Dept Med & Rheumatol, Los Angeles, CA 90048 USA
关键词
D O I
10.1007/s00198-007-0490-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Salmon calcitonin, available as a therapeutic agent for more than 30 years, demonstrates clinical utility in the treatment of such metabolic bone diseases as osteoporosis and Paget's disease, and potentially in the treatment of osteoarthritis. This review considers the physiology and pharmacology of salmon calcitonin, the evidence based research demonstrating efficacy and safety of this medication in postmenopausal osteoporosis with potentially an effect on bone quality to explain its abilities to reduce the risk of spine fracture, the development of an oral salmon calcitonin preparation, and the therapeutic rationale for this preparation's chondroprotective effect in osteoarthritis.
引用
收藏
页码:479 / 491
页数:13
相关论文
共 113 条
[91]   Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy [J].
Sarkar, S ;
Mitlak, BH ;
Wong, MM ;
Stock, JL ;
Black, DM ;
Harper, KD .
JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 (01) :1-10
[92]   Calcitonin promotes osteoclast survival in vitro [J].
Selander, KS ;
Harkonen, PL ;
Valve, E ;
Monkkonen, J ;
Hannuniemi, R ;
Vaananen, HK .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1996, 122 (02) :119-129
[93]   CENTRAL-NERVOUS-SYSTEM BINDING-SITES FOR CALCITONIN AND CALCITONIN GENE-RELATED PEPTIDE [J].
SEXTON, PM .
MOLECULAR NEUROBIOLOGY, 1991, 5 (2-4) :251-273
[94]   The analgesic role of calcitonin following osteoporotic fracture [J].
Silverman, SL ;
Azria, M .
OSTEOPOROSIS INTERNATIONAL, 2002, 13 (11) :858-867
[95]   Quality-of-life issues in osteoporosis. [J].
Silverman S.L. .
Current Rheumatology Reports, 2005, 7 (1) :39-45
[96]   EVALUATION OF ANTIBODIES AND CLINICAL RESISTANCE TO SALMON CALCITONIN [J].
SINGER, FR ;
POTTS, JT ;
KRANE, SM ;
BLOCH, KJ ;
ALDRED, JP .
JOURNAL OF CLINICAL INVESTIGATION, 1972, 51 (09) :2331-+
[97]   Goals of treatment for Paget's disease of bone [J].
Siris, ES .
JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 :49-52
[98]   Acute effects of calcitonin nasal spray on serum C-telopeptide of type 1 collagen (CTx) levels in elderly osteopenic women with increased bone turnover [J].
Srivastava, AK ;
Libanati, C ;
Hohmann, O ;
Kriegman, A ;
Baylink, DJ .
CALCIFIED TISSUE INTERNATIONAL, 2004, 75 (06) :477-481
[99]   Calcitonin receptor polymorphism is associated with a decreased fracture risk in post-menopausal women [J].
Taboulet, J ;
Frenkian, M ;
Frendo, JL ;
Feingold, N ;
Jullienne, A ;
de Vernejoul, MC .
HUMAN MOLECULAR GENETICS, 1998, 7 (13) :2129-2133
[100]   DOWN-REGULATION OF CALCITONIN RECEPTOR MESSENGER-RNA EXPRESSION BY CALCITONIN DURING HUMAN OSTEOCLAST-LIKE CELL-DIFFERENTIATION [J].
TAKAHASHI, S ;
GOLDRING, S ;
KATZ, M ;
HILSENBECK, S ;
WILLIAMS, R ;
ROODMAN, GD .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (01) :167-171